Targeting HER2(+) breast cancer: the TBK1/IKKε axis

HER2(+) breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or neoadjuvant chemotherapy plus anti-HER2 agents such as trastuzumab, a monoclonal antibody directed against HER2. Despite improvement in disease free survival, most patient...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoscience
Auteurs principaux: Jiang, Zhe, Liu, Jeff C., Chung, Philip E.D., Egan, Sean E., Zacksenhaus, Eldad
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2014
Sujets:
Research Perspective
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4278282/
https://ncbi.nlm.nih.gov/pubmed/25594009
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires